The BioPharm Brief

BioPharm Brief is a daily podcast that synthesizes BioPharm International®’s coverage into concise, insight-driven updates on biopharmaceutical research, clinical and drug development trends, and evolving industry strategies.

BioPharm_Brief_Logo.jpg 

]]> https://audioboom.com/channels/5167274 audioboom.com Mon, 30 Mar 2026 21:16:14 +0000 en-us https://audioboom.com/i/43470496/s=1400x1400/el=1/rt=fill.png The BioPharm Brief https://audioboom.com/channels/5167274 false The BioPharm Brief Audioboom 577675f9-6c92-5654-b270-eaff36557160 https://audioboom.com/channels/5167274.rss episodic The BioPharm Brief: Talking Lifecycle Optimization, Strategic Investment, and Collaboration Shaping Growth Trajectory https://audioboom.com/posts/8880737 141 false full Welcome to The BioPharm Brief, your daily snapshot of the developments shaping biopharmaceutical research, regulatory progress, and industry strategy. Today’s update highlights a regulatory milestone in neuromuscular disease alongside broader industry perspectives on innovation, investment, and collaboration driving long-term growth. Mon, 30 Mar 2026 21:16:14 +0000 tag:audioboom.com,2026-03-30:/posts/8880737 The BioPharm Brief The BioPharm Brief The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases? https://audioboom.com/posts/8878318 147 false full Welcome to The BioPharm Brief, your daily snapshot of key developments shaping biopharmaceutical innovation and clinical strategy. Today’s update highlights continued momentum in next-generation T-cell engager platforms, driven by both early-stage financing and large biopharma partnerships targeting complex diseases. First, Excalipoint Therapeutics has launched with $68.7 million in seed financing to advance a portfolio of multi-specific T-cell engager platforms. The company is developing several proprietary technologies designed to overcome longstanding challenges in T-cell engager therapies, particularly in solid tumors, for which issues such as limited tumor penetration and immunosuppressive microenvironments have constrained efficacy. Tue, 24 Mar 2026 20:04:21 +0000 tag:audioboom.com,2026-03-24:/posts/8878318 The BioPharm Brief The BioPharm Brief The BioPharm Brief: Investments in Next-Gen Modalities Drive Oncology and Metabolic Therapy Development https://audioboom.com/posts/8876246 121 false full Welcome to The BioPharm Brief, your daily snapshot of key developments in biopharmaceutical research, innovation, and clinical progress. Today’s update highlights fresh funding for T‑cell engager platforms and continued momentum in multi‑agonist metabolic therapy development. Thu, 19 Mar 2026 18:45:59 +0000 tag:audioboom.com,2026-03-19:/posts/8876246 The BioPharm Brief The BioPharm Brief The BioPharm Brief: IL-23 Pathway Expansion Signals Next Wave of Immunology Lifecycle Development https://audioboom.com/posts/8874701 126 false full Welcome to The BioPharm Brief, your daily snapshot of the developments shaping biopharmaceutical research, regulatory progress, and clinical innovation. Today’s update focuses on a regulatory milestone that could further expand treatment options for patients living with psoriatic arthritis. In the United States, FDA has accepted for review a supplemental biologics license application for tildrakizumab from Sun Pharmaceutical Industries, seeking approval to treat adults with active psoriatic arthritis. Tildrakizumab, marketed as Ilumya, is a monoclonal antibody that selectively targets the interleukin-23 pathway, a key inflammatory driver in several immune-mediated diseases. The therapy is already approved in the US for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Mon, 16 Mar 2026 20:12:19 +0000 tag:audioboom.com,2026-03-16:/posts/8874701 The BioPharm Brief The BioPharm Brief The BioPharm Brief: FDA Priority Review and Trispecific Antibodies Advance Precision Oncology https://audioboom.com/posts/8871658 114 false full Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research and clinical innovation. Today’s podcast highlights advances in targeted oncology therapies, from antibody‑drug conjugates, or ADCs, to next‑generation multispecific antibodies, and how these innovations are moving through regulatory and clinical pathways. Mon, 09 Mar 2026 20:16:25 +0000 tag:audioboom.com,2026-03-09:/posts/8871658 The BioPharm Brief The BioPharm Brief The BioPharm Brief: Data-Driven Trial Design and Bispecific Checkpoint Immunotherapy Advance Oncology Development https://audioboom.com/posts/8870299 127 false full In today’s podcast, integrated biomarker modeling and dual-pathway immune checkpoint modulation highlight evolving strategies to improve translational efficiency and durability in oncology trials. Thu, 05 Mar 2026 21:31:33 +0000 tag:audioboom.com,2026-03-05:/posts/8870299 The BioPharm Brief The BioPharm Brief The BioPharm Brief: New Glioblastoma Combo Immunotherapy Advances Adaptive Neuro-Oncology Trials https://audioboom.com/posts/8869493 133 false full Welcome to The BioPharm Brief, your daily snapshot of key developments in biopharmaceutical research and clinical innovation. Today we’re looking at a new collaborative immunotherapy approach for one of the most challenging solid tumors, glioblastoma multiforme, and what it could mean for future neuro‑oncology strategies. Wed, 04 Mar 2026 20:00:39 +0000 tag:audioboom.com,2026-03-04:/posts/8869493 The BioPharm Brief The BioPharm Brief The BioPharm Brief: Strategic Partnerships, CGT Infrastructure, and Triple-Agonist Metabolic Innovation Drive Drug Development Evolution https://audioboom.com/posts/8866225 149 false full Welcome to The BioPharm Brief, your daily overview of the scientific, operational, and strategic developments shaping today’s biopharmaceutical industry. Today’s coverage highlights how collaboration models, advanced therapy infrastructure, and next-generation metabolic science are evolving together as companies work to manage increasing development complexity across modern drug pipelines. Wed, 25 Feb 2026 19:49:13 +0000 tag:audioboom.com,2026-02-25:/posts/8866225 The BioPharm Brief The BioPharm Brief The BioPharm Brief: Trial Recruitment Challenges and Reshaping Workforce Strategies https://audioboom.com/posts/8865579 146 false full Welcome to The BioPharm Brief, where we break down the latest developments shaping biopharmaceutical research, clinical progress, and industry strategy. Today’s podcast looks at how clinical trial realities and workforce evolution continue to influence drug development decisions and the future adoption of advanced therapies across the industry. Tue, 24 Feb 2026 21:27:05 +0000 tag:audioboom.com,2026-02-24:/posts/8865579 The BioPharm Brief The BioPharm Brief The BioPharm Brief: Long-Term Clinical Durability Advances Rare Disease Treatment Strategies https://audioboom.com/posts/8865010 131 false full Today’s podcast highlights how sustained clinical efficacy data in alpha-thalassemia and ulcerative colitis highlight durability as a defining benchmark in modern biologic drug development. Mon, 23 Feb 2026 21:34:15 +0000 tag:audioboom.com,2026-02-23:/posts/8865010 The BioPharm Brief The BioPharm Brief The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends https://audioboom.com/posts/8864090 127 false full Today’s BioPharm Brief highlights key regulatory, clinical, and therapeutic development updates shaping the biopharma landscape. Recent coverage from BioPharm International reflects how evolving clinical science, rare disease innovation, and regulatory modernization continue to influence drug development strategy and approval pathways across the industry. Fri, 20 Feb 2026 22:22:56 +0000 tag:audioboom.com,2026-02-20:/posts/8864090 The BioPharm Brief The BioPharm Brief